The relationship of major depressive disorder with Crohn's disease activity

Facanali, Carolina Bortolozzo Graciolli; Sobrado, Carlos Walter; Fráguas, Renério; Facanali, Marcio Roberto; Boarini, Lucas Rodrigues; Sobrado, Lucas Faraco; Ivan, Cristina

doi:10.1016/j.clinsp.2023.100188

Cited by 6 publications

(3 citation statements)

References 53 publications

(77 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two meta-analyses[ 1 , 11 ] determined that the occurrence rate of depressive symptoms in IBD patients was around 25.2% and 21.6%, respectively. Likewise, the occurrence rate of depression in CD patients varied from 17.5% in a survey based on a primary care database in the United Kingdom to 41.7% in a different study that examined a population-based group[ 18 , 19 ]. The existing findings on the prevalence of depression in IBD were still multiform.…”

Section: Discussionmentioning

confidence: 99%

Prevalence and risk factors of depression among patients with perianal fistulizing Crohn’s disease

Li,

Ng,

Qiao

et al. 2024

World J Psychiatry

View full text Add to dashboard Cite

BACKGROUND Psychological distress, especially depression, associated with perianal fistulizing Crohn’s disease (PFCD) is widespread and refractory. However, there is a surprising paucity of studies to date that have sought to identify the prevalence and risk factors of depression associated with PFCD. AIM To estimate the prevalence of depressive symptoms and investigate the depression-related risk factors in patients with PFCD. METHODS The study was conducted in the form of survey and clinical data collection via questionnaire and specialized medical staff. Depressive symptoms, life quality, and fatigue severity of patients with PFCD were assessed by Patient Health Questionnaire-9, Inflammatory Bowel Disease Patient Quality of Life Questionnaire (IBDQ), and Inflammatory Bowel Disease (IBD) Fatigue Patient Self-assessment Scale. The basic demographic information, overall disease features, perianal clinical information, and laboratory inflammation indicators were also gathered. Multivariate regression analysis was ultimately used to ascertain the risk factors of depression associated with PFCD. RESULTS A total of 123 patients with PFCD were involved, and 56.91% were suffering from depression. According to multivariate logistic regression analysis, Perianal Disease Activity Index (PDAI) score [odds ratio (OR) = 0.69, 95% confidence interval (CI): 0.50 to 0.95], IBDQ score (OR = 0.93, 95%CI: 0.88 to 0.97), modified Van Assche index (OR = 1.24, 95%CI: 1.01 to 1.53), and IBD Fatigue score (OR = 1.72, 95%CI: 1.23 to 2.42) were independent risk factors of depression-related prevalence among patients with PFCD (P < 0.05). Multiple linear regression analysis revealed that the increasing perianal modified Van Assche index (β value = 0.166, 95%CI: 0.02 to 0.31) and decreasing IBDQ score (β value = -0.116, 95%CI: -0.14 to -0.09) were independently associated with the severity of depression (P < 0.05). CONCLUSION Depressive symptoms in PFCD patients have significantly high prevalence. PDAI score, modified Van Assche index, quality of life, and fatigue severity were the main independent risk factors.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence and risk factors of depression among patients with perianal fistulizing Crohn’s disease

Li,

Ng,

Qiao

et al. 2024

World J Psychiatry

View full text Add to dashboard Cite

show abstract

“…There exists a fair library of research linking MDD to IBD and its subtypes, Crohn's disease (CD) and ulcerative colitis (UC). Shared factors between the two disorders include the dysregulation of the GBA (Fadgyas-Stanculete et al, 2014), microbiota and IEB function (Jeffery et al, 2012;Kelly et al, 2015;Yuan et al, 2021), stress (Mawdsley and Rampton, 2005;Goodhand et al, 2012), immune dysregulation (Persoons et al, 2005), and increased circulating proinflammatory cytokines (Alexakis et al, 2017;Facanali et al, 2023). Additionally, IBD and MDD also share disease implicated metabolites such as SCFAs and those involved in the tryptophan pathway (Banfi et al, 2021).…”

Section: Tetrathionate Concentrations In the Gut As A Predictor Of Mddmentioning

confidence: 99%

“…Specifically, one study by Addolorato et al (1997) showed a significantly higher percentage of individuals with depression in CD and UC patients than in controls (41.9% versus 11.1%, and 50.0% versus 11.1%, respectively). Some studies also indicate that disease activity is influenced by depression and that disease duration can be inversely correlated with MDD presence (Goodhand et al, 2012;Byrne et al, 2017;Facanali et al, 2023). Further, a prospective study by Persoons et al (2005) found that after treatment with infliximab, an anti-TNF therapy, patients with MDD at baseline achieved remission significantly less (29%) in comparison to non-depressed patients (70%) and required re-treatment.…”

Section: Tetrathionate Concentrations In the Gut As A Predictor Of Mddmentioning

confidence: 99%

The development of an ingestible biosensor for the characterization of gut metabolites related to major depressive disorder: hypothesis and theory

Densil,

George,

Mahdi

et al. 2023

Front. Syst. Biol.

View full text Add to dashboard Cite

The diagnostic process for psychiatric conditions is guided by the Diagnostic and Statistical Manual of Mental Disorders (DSM) in North America. Revisions of the DSM over the years have led to lowered diagnostic thresholds across the board, incurring increased rates of both misdiagnosis and over-diagnosis. Coupled with stigma, this ambiguity and lack of consistency exacerbates the challenges that clinicians and scientists face in the clinical assessment and research of mood disorders such as Major Depressive Disorder (MDD). While current efforts to characterize MDD have largely focused on qualitative approaches, the broad variations in physiological traits, such as those found in the gut, suggest the immense potential of using biomarkers to provide a quantitative and objective assessment. Here, we propose the development of a probiotic Escherichia coli (E. coli) multi-input ingestible biosensor for the characterization of key gut metabolites implicated in MDD. DNA writing with CRISPR based editors allows for the molecular recording of signals while riboflavin detection acts as a means to establish temporal and spatial specificity for the large intestine. We test the feasibility of this approach through kinetic modeling of the system which demonstrates targeted sensing and robust recording of metabolites within the large intestine in a time- and dose- dependent manner. Additionally, a post-hoc normalization model successfully controlled for confounding factors such as individual variation in riboflavin concentrations, producing a linear relationship between actual and predicted metabolite concentrations. We also highlight indole, butyrate, tetrahydrofolate, hydrogen peroxide, and tetrathionate as key gut metabolites that have the potential to direct our proposed biosensor specifically for MDD. Ultimately, our proposed biosensor has the potential to allow for a greater understanding of disease pathophysiology, assessment, and treatment response for many mood disorders.

show abstract

Disease severity is associated with depressive symptoms and suicidal thoughts in Brazilian patients with inflammatory bowel disease

Facanali,

Roncete,

Damiano

et al. 2023

General Hospital Psychiatry

View full text Add to dashboard Cite

The relationship of major depressive disorder with Crohn's disease activity

Cited by 6 publications

References 53 publications

Prevalence and risk factors of depression among patients with perianal fistulizing Crohn’s disease

Prevalence and risk factors of depression among patients with perianal fistulizing Crohn’s disease

The development of an ingestible biosensor for the characterization of gut metabolites related to major depressive disorder: hypothesis and theory

Disease severity is associated with depressive symptoms and suicidal thoughts in Brazilian patients with inflammatory bowel disease

Contact Info

Product

Resources

About